How can we effectively prevent cancer today against the background of a sharp increase in the number of cancer cases in the developed world, even though mortality is declining due to better cancer therapies?

At our Cancer Prevention Center, we will be bringing to bear all the experience we have gained during the last twenty years and focusing all of our resources on addressing this issue. We believe that our leading expertise especially in epigenetics makes us ideally placed

to develop more effective cancer prevention strategies at the highest level and to then integrate them into our health care programs. The SCPC strategy involves effective use of the three main protective mechanisms against cancer:

1. EpiGenetic management of tumor suppressor genes

95% of all serious illnesses arise from epigenetic changes triggered by environmental influences which are actually largely controllable and thus preventable. Only 5% are purely hereditary diseases, i.e. genetically determined. It is a similar situation with cancer. At the forefront of our strategy is the identification of each individual’s personal triggers for positively influencing his or her vital tumor suppressor genes. These are fundamental to correct cancer cell apoptosis functioning.

2. Optimization of the immune defense system

Tumor cells play a really nasty trick: they slow down the working of the immune cells that are there to defend against them. We counter this effect, employing technology that was awarded the 2018 Nobel Prize for Medicine. It was developed by James Allison of the USA and his Japanese colleague Tasuku Honjo. The two scientists were honored for the development of new cancer therapies in which activation of the body’s own immune system against tumor cells plays a central role. The basis for this is the respective T-cell diagnosis, which is a standard component of the Salvagene Premium package.

3. Bolstering the individual’s own apoptosis functioning

Strengthening of individual apoptosis performance is achieved with a naturalsubstrate developed by us, called Salvastrol. Salvastrols have strong anti-cancer properties which are activated and metabolized by CYP1B1, a member of the cytochrome P450 family of enzymes. CYP1B1 is a detoxifying enzyme which is fairly active in cancer cells whilst not occurring in healthy cells. The interaction of salvastrols with CYP1B1 produces a metabolite which induces apoptosis (programmed cell death) in the diseased cells. In this way, existing, diseased cells and cancer cells can be greatly reduced.

Salvagene Prostate Cancer Prevention Program

On the basis of our algorhythm system developed with leading research institutes in Europe, we have produced the world’s first Prostate Cancer Prevention Program.